Loading
A phase 3 trial of Encorafenib, Binimetinib, Pembrolizumab in melanoma, run by Pfizer, active and no longer recruiting.
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma is a phase 3 interventional study registered as NCT04657991 by Pfizer, with 257 participants enrolled, started 2021-01-15 and due to reach its primary completion in 2026-10-30. Interventions recorded: Encorafenib, Binimetinib, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV).
Shares Encorafenib, Pfizer (incl. Seagen), Pembrolizumab, Small-molecule kinase inhibitors.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Pfizer (incl. Seagen), Melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Small-molecule kinase inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.